FindTrial
Sign In

Clinical Observation and Research on the Evaluation of Therapeutic Efficacy and Minimal Residual Disease in Patients with Diffuse Large B-cell Lymphoma through Dynamic Monitoring of ctDNA in Peripheral Blood and Cerebrospinal Fluid

Clinical Observation and Research on the Evaluation of Therapeutic Efficacy and Minimal Residual Disease in Patients with Diffuse Large B-cell Lymphoma through Dynamic Monitoring of ctDNA in Peripheral Blood and Cerebrospinal Fluid

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500112431
Enrollment
Unknown
Registered
2025-11-13
Start date
2025-12-01
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse large B-cell lymphoma

Interventions

Observation group:None

Sponsors

Department of Hematology, Fifth Medical Center of the PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients aged 18 years or older, newly diagnosed with DLBCL confirmed by histopathology (immunohistochemistry, molecular testing).

Exclusion criteria

Exclusion criteria: Having received systematic treatment for DLBCL or being involved in other clinical trial interventions may affect the dynamic monitoring of ctDNA.

Design outcomes

Primary

MeasureTime frame
Positive rate;mutant gene;—

Countries

China

Contacts

Public ContactWenrong Huang

Department of Hematology, Fifth Medical Center of the PLA General Hospital

Huangwr301@163.com+86 139 1036 8737

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026